Gilead Sciences (GILD) Stock Overview

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More details

GILD fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	4/6
Financial Health	3/6
Dividends	5/6

Rewards

Trading at 54% below our estimate of its fair value

Earnings are forecast to grow 10.51% per year

Earnings grew by 1129.9% over the past year

Pays a reliable dividend of 2.9%

Risk Analysis

Large one-off items impacting financial results

Has a high level of debt

GILD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Gilead Sciences
Historical stock prices
Current Share Price	US$89.71
52 Week High	US$95.78
52 Week Low	US$79.49
Beta	0.31
1 Month Change	0%
3 Month Change	0%
1 Year Change	36.86%
3 Year Change	36.86%
5 Year Change	15.78%
Change since IPO	18.51%

Recent updates

Shareholder Returns

	GILD	CL Biotechs	CL Market
7D	0%	0%	0%
1Y	36.9%	0%	0%

Return vs Industry: GILD exceeded the CL Biotechs industry which returned -5.5% over the past year.

Return vs Market: GILD exceeded the CL Market which returned 18.1% over the past year.

Price Volatility

Is GILD's price volatile compared to industry and market?
GILD volatility
GILD Average Weekly Movement	0%
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in CL Market	0%
10% least volatile stocks in CL Market	0%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine GILD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1987	17,600	Dan O'Day	www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GILD fundamental statistics
Market cap	US$135.61b
Earnings (TTM)	US$5.97b
Revenue (TTM)	US$28.74b

22.7x

P/E Ratio

4.7x

P/S Ratio

Is GILD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GILD income statement (TTM)
Revenue	US$28.74b
Cost of Revenue	US$6.24b
Gross Profit	US$22.50b
Other Expenses	US$16.53b
Earnings	US$5.97b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	4.80
Gross Margin	78.29%
Net Profit Margin	20.76%
Debt/Equity Ratio	130.8%

How did GILD perform over the long term?

See historical performance and comparison

Dividends

2.9%

Current Dividend Yield

65%

Payout Ratio

Does GILD pay a reliable dividends?

See GILD dividend history and benchmarks

When do you need to buy GILD by to receive an upcoming dividend?
Gilead Sciences dividend dates
Ex Dividend Date	Jun 13 2025
Dividend Pay Date	Jun 27 2025
Days until Ex dividend	7 days
Days until Dividend pay date	21 days

Does GILD pay a reliable dividends?

See GILD dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/06/05 14:15
End of Day Share Price	2025/06/04 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gilead Sciences, Inc. is covered by 71 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Brian Skorney	Baird
Ishan Majumdar	Baptista Research

Gilead Sciences (GILD) Stock Overview

Rewards

Risk Analysis

Gilead Sciences, Inc. Competitors

Amgen

CSL

AbbVie

Regeneron Pharmaceuticals

Price History & Performance

Recent News & Updates

Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of Trodelvy

Gilead's Livdelzi (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented At EASL 2025

Gilead Sciences, Inc. to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

Gilead Sciences, Inc. Declares Quarterly Dividend for the Second Quarter of 2025, Payable on June 27, 2025

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-04/KeyNOTE-D19 Study

Recent updates

Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of Trodelvy

Gilead's Livdelzi (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented At EASL 2025

Gilead Sciences, Inc. to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

Gilead Sciences, Inc. Declares Quarterly Dividend for the Second Quarter of 2025, Payable on June 27, 2025

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-04/KeyNOTE-D19 Study

Gilead Sciences, Inc. to Report Q1, 2025 Results on Apr 24, 2025

Gilead Sciences, Inc., Annual General Meeting, May 07, 2025

Gilead Sciences, Inc. Presents New HIV Treatment and Cure Research Data At CROI 2025, Including an Investigational Long-Acting, Twice-Y Early Therapy Option

European Medicines Agency Validates Gilead's Marketing Authorization Application and Eu-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv Prevention

Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

Gilead Sciences, Inc. Announces U.S. FDA Acceptance of Its New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2025

Full year 2024 earnings released: EPS: US$0.39 (vs US$4.54 in FY 2023)

Gilead Sciences, Inc. Announces Increase in First Quarter 2025 Dividend, Payable on March 28, 2025

Insufficient new directors

Gilead Sciences, Inc. to Report Q4, 2024 Results on Feb 11, 2025

Insufficient new directors

Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Kite, Gilead Company, Announces Results from Four Analyses That Continue to Demonstrate Durability of Response of Tecartus in Patients with R/R MCL and R/R B-ALL During 66th ASH Annual Meeting and Exposition

Gilead Sciences, Inc.' Company Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH

Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 Results

Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Third quarter dividend of US$0.77 announced

Third quarter 2024 earnings released: EPS: US$1.01 (vs US$1.75 in 3Q 2023)

Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Upcoming dividend of US$0.77 per share

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Second quarter 2024 earnings released: EPS: US$1.29 (vs US$0.84 in 2Q 2023)

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

New minor risk - Profit margin trend

First quarter 2024 earnings released: US$3.34 loss per share (vs US$0.81 profit in 1Q 2023)

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Upcoming dividend of US$0.77 per share

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Shareholder Returns

Price Volatility

About the Company

Gilead Sciences, Inc. Fundamentals Summary